SCHEMBL1490650

SCHEMBL1490650

COC(=O)c1c(NC(=O)c2ccc(Cl)cc2)csc1-c1ccc(F)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.52
▸ LMNA P02545 3/20 0.52
▸ KMT2A Q03164 3/20 0.52
▸ POLB P06746 1/20 0.52
▸ CYP1A2 P05177 1/20 0.48
▸ CYP2D6 P10635 1/20 0.48
▸ TSHR P16473 1/20 0.48
▸ CYP2C19 P33261 1/20 0.48
▸ SMN1; SMN2 Q16637 3/20 0.47
▸ ALDH1A1 P00352 2/20 0.47
▸ HPGD P15428 1/20 0.47
▸ CNR2 P34972 2/20 0.47
▸ PTGS1 P23219 1/20 0.46
▸ KCNMA1 Q12791 1/20 0.46
▸ NPC1 O15118 2/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ ATM Q13315 1/20 0.46
▸ KDM4E B2RXH2 3/20 0.46
▸ ADCY1 Q08828 1/20 0.44
▸ TP53 P04637 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1490441 0.89 LMNA (0.52) MAPTLMNAKMT2APOLBCYP1A2
SCHEMBL1490520 0.87 MEN1 (0.49) MAPTLMNAKMT2ASMN1; SMN2ALDH1A1
SCHEMBL1490393 0.87 MEN1 (0.49) MAPTLMNAKMT2ASMN1; SMN2ALDH1A1
SCHEMBL1490469 0.83 MAPT (0.74) MAPTLMNAKMT2APOLBCYP1A2
SCHEMBL1490509 0.80 KMT2A (0.55) MAPTLMNAKMT2ASMN1; SMN2ALDH1A1
SCHEMBL3631128 0.80 MAPT (0.66) MAPTLMNAKMT2ATSHRALDH1A1
SCHEMBL12756878 0.80 KMT2A (0.56) MAPTLMNAKMT2ACYP1A2CYP2C19
SCHEMBL15477195 0.78 KDM4E (0.47) MAPTLMNAKMT2APOLBCYP1A2
SCHEMBL1490465 0.78 MAPT (0.52) MAPTLMNAKMT2APOLBCYP1A2
SCHEMBL1490436 0.78 MAPT (0.52) MAPTLMNAKMT2APOLBCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140051711-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA INC. (US) 2014-02-20 — — US disclosed
US-8618307-B2 Compounds that modulate intracellular calcium CALCIMEDICA, INC. (US) 2013-12-31 — — US disclosed
EP-2477982-A2 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM Calcimedica, Inc. (US) 2012-07-25 — — EP disclosed
WO-2011034962-A2 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA INC. (US) 2011-03-24 — — WO disclosed
US-20110065724-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA, INC. (US) 2011-03-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051711-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM ORAI1, SARAF, RYR2 MAPT 1478/4885LMNA 1306/4885KMT2A 4706/4885
US-20110065724-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM ORAI1, SARAF, RYR2 MAPT 1478/4885LMNA 1306/4885KMT2A 4706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback